RPRX
Is Royalty Pharma (RPRX) undervalued?
Royalty Pharma (RPRX) currently trades at a P/E of 27.6x with an owner-earnings yield of 11.0%. The Buffett-Fit valuation pillar, owner-earnings yield, intrinsic-value multiple, and the company's underlying compounding rate, is the framework used on this page to grade undervaluation. Educational only, not investment advice.
Headline multiples. Royalty Pharma trades at a trailing P/E of 27.6x, a P/B of 3.31x, and an EV-to-EBIT of 19.9x. None of these in isolation tells you whether the stock is undervalued: a 30x P/E is cheap for a quality compounder and expensive for a cyclical commodity producer. The point is the relationship between price and the underlying business quality on the same scale.
Owner-earnings yield. Royalty Pharma's owner-earnings yield (free cash flow / enterprise value) currently sits at 11.0%. This is Buffett's preferred valuation lens because it asks "what does the business actually return to a 100% owner?" rather than accounting earnings that can be inflated by accruals. A yield above the 10-year Treasury plus a 4-5% equity-risk premium is the rough benchmark for "cheap" against a high-quality business.
Earnings yield (1/P/E). The inverted P/E gives an earnings yield of 3.6%, useful as a sanity-check against the owner-earnings yield above. Large gaps between the two usually mean either high stock-based compensation eroding cash earnings (yield gap negative) or aggressive working-capital management inflating cash earnings vs accounting earnings (yield gap positive).
What the framework concludes. Valuation alone doesn't decide whether RPRX is a buy, Buffett's full rule is "a wonderful business at a fair price beats a fair business at a wonderful price." The valuation sub-score in the Buffett-Fit verdict on this page combines the metrics above with the company's underlying compounding rate (ROIC × reinvestment) to produce a single 0-100 number. Read the full verdict to see how it sits alongside moat strength, durability, management, and financial health.
How invest-like measures this
Valuation on invest-like.com is graded against three benchmarks: the owner-earnings yield (Buffett's preferred metric, free cash flow divided by enterprise value), the multiple of intrinsic value (DCF and reverse-DCF), and the price relative to the company's underlying compounding rate.
The score weighs these against the sector's median quality benchmarks: a 20x P/E is cheap for a software compounder and expensive for a cyclical commodity producer, so the sector-relative bonus matters. Educational only, not investment advice.
Es un análisis educativo basado en métodos de inversión. No es asesoramiento ni una recomendación, y no conoce tu situación. Investiga por tu cuenta antes de decidir.
